Our Latest News - BUHLMANN

BUHLMANN News

Usability of IBDoc- Novel Fecal Calprotectin Home-Based Rapid Test

IBDoc® Citation: Røer MJ., 2019, Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice, Point of Care: September 2019 - Volume 18 - Issue 3 - p 85–91. doi: 10.1097/POC.0000000000000192 Highlights from this Publication “Clearly, the majority of the IBD patients found the home-based test valuable...” Read Citation Health Canada License: 98903
Continue Reading

IBDoc Learning with Video Tutorials

New IBDoc® Tutorials (available on: ibdoc.net) IBDoc® Portal Tutorial videos offer: Quick and easy training for the sites to learn the important portal functionalities Updated healthcare professional and patient training Who Are the Videos for? Clinical Administrators Clinical Users View these six new IBDoc® Portal Tutorial Videos. They are geared toward helping Healthcare Professionals that
Continue Reading

BÜHLMANN fCAL® turbo Success Story- Freeman Hospital, Newcastle

The Benefits of Switching to BÜHLMANN Assay for Calprotectin Testing Dr. Elodie Hanon, Prinicpal Clinial Scientist at the Freeman Hospital, Newcastle, UK (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article "We went live with the fCAL turbo in March 2018, and there really have been no issues. The turn-around time
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for CALEX®Cap Stool Preparation Device

BÜHLMANN CALEX® Cap, a single use tube intended for the preparation of human stool samples to be used with the BÜHLMANN fCAL® turbo, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United
Continue Reading

The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo: Schallberger, Y. et al. The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo. Swiss MedLab 2016, 13. – 16. June 2016. Berne, Switzerland. Poster Highlights from this Publication “ ...Combined with the CALEX® Cap extraction device the fecal calprotectin testing workflow is further simplified thus reducing hands-on-time by 70%. " Read Citation
Continue Reading

CALEX® Cap

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. CALEX® Cap Stool Preparation Device- for fecal Calprotectin & fecal Pancreatic Elastase The BÜHLMANN CALEX® Cap is designed to provide convenient and safe stool extraction of multiple analytes. The optimized dilution of stool sample yields maximum extraction efficiency and analyte stability. Calprotectin
Continue Reading

Four Years of Experience Using IBDoc

Benefits for Patients and Healthcare Staff of Routine IBDoc® Use Kathleen Sugrue, Advanced Nurse Practitioner at Mercy University Hospital, Cork (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article “Since introducing IBDoc® we get less calls on the helpline because patients can check themselves if they are concerned they are flaring.” “Patients
Continue Reading

Patient’s Perspective- One Year using IBDoc

Read a recent article written from the perspective of a long term Crohn's sufferer who shares his experience of managing the disease with the help of calprotectin self-testing. Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories. Highlight from this Perspective Article “It has reduced the “waiting time” for results down to hours instead of days or
Continue Reading

Labsense News Summer 2019 Edition


Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® turbo Automated Calprotectin Test

BÜHLMANN fCAL® turbo, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 26, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United States Food and Drug
Continue Reading